Australia markets open in 3 hours 5 minutes

Lumos Pharma, Inc. (LUMO)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.18-0.07 (-0.97%)
At close: 04:00PM EST
7.18 0.00 (0.00%)
After hours: 05:39PM EST

Lumos Pharma, Inc.

4200 Marathon Boulevard
Suite 200
Austin, TX 78756
United States
512 215 2630

Full-time employees31

Key executives

NameTitlePayExercisedYear born
Mr. Richard J. HawkinsCEO & Chairman1.27MN/A1949
Dr. John C. McKew Ph.D.Chief Scientific Officer & Pres747.99kN/A1964
Mr. Bradley J. Powers J.D.Chief Compliance Officer & Gen. Counsel677.08kN/A1979
Mr. Carl W. LangrenConsultant717.99kN/A1955
Ms. Lori D. Lawley CPACFO & Principal Accounting OfficerN/AN/A1984
Lisa MillerSr. Director of Investor RelationsN/AN/AN/A
Mr. Aaron Schuchart B.B.A., CPA, M.B.A.Chief Bus. OfficerN/AN/A1965
Dr. David B. Karpf B.A., M.D.Chief Medical OfficerN/AN/A1955
Mr. Eddie L. Varnado M.B.A.VP of Fin. & Corp. ControllerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.

Corporate governance

Lumos Pharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.